It has been a research focus to uncover the genetic determination of complex diseases caused by rare variants. As the vast majority of genomic variants represent background variation, highlighting potentially causal mutations through a weighting scheme is critical to the success of association studies aimed at identifying rare variants. In this study, we propose a novel Bayesian marker selection approach to perform a weighting-based association test. In this approach, an individual association signal and its direction are used to weight variants. In addition, the predicted biological function of variants is taken as prior information to direct the selection of likely causal variants. Simulation studies show that the proposed method has improved power over several existing methods in certain conditions. Analyses of two empirical datasets demonstrate its applicability.
Introduction
Though common variant aimed genome-wide association studies (GWASs) have identified hundreds of single nucleotide polymorphisms (SNPs) associated with a variety of complex diseases and traits (http://www.genome.gov/gwastudies), it is still unclear why the identified variants explain only a small portion of phenotypic variation (Manolio et al., 2009) . Until recently, it has been recognised that the "missing" heritability may be accounted for by variants with lower frequencies but with a much larger numbers across the human genome. A variety of theoretical and experimental studies have shown that multiple rare variants are as important as common variants in determining the aetiology of complex diseases and the variation of traits (Pritchard, 2001; Pritchard & Cox, 2002; Cohen et al., 2004; Cohen et al., 2006; Ahituv et al., 2007a; Kryukov et al., 2007; Ji et al., 2008; Tarpey et al., 2009) , and extensive evidence continues to emerge. Thus, it has been a research focus to uncover the genetic determination caused by rare variants for most complex diseases. To depict an exhaustively unbiased map of rare variants across the genome, the 1000 genomes project (Siva, 2008) was launched with the aim of sequencing at least 1000 human genomes in various populations. The densest map of rare variants that the project identifies, together with advances in next-generation sequencing technologies (Tucker et al., 2009) , will promote the next wave of rare variant aimed association studies by sequencing a portion or even the entire of the genome in a large number of individuals.
Due to allelic heterogeneity (Pritchard & Cox, 2002 ) and rarity of variants, conventional one-by-one statistical analyses are inefficient for rare variants. As solutions, a variety of specific methods have been proposed (Madsen & Browning, 2009; Bansal et al., 2010; Bhatia et al., 2010; Han & Pan, 2010; Li et al., 2010; Liu & Leal, 2010; Price et al., 2010; Zhang et al., 2010a; Zhang et al., 2010b; Zhu et al., 2010; Ionita-Laza et al., 2011; Sul et al., 2011; Yi & Zhi, 2011) . One of these proposed analysis strategies is to take the genomic region that contains multiple rare variants as the unit of analysis (Li & Leal, 2008) . This is achieved by merging the information contained in multiple variants together and examining the association by analysis of the merged signal. Ideally, rare variants to be merged should be homogeneous in the sense that all are irrelevant to or associated with the phenotype, and in the latter case, in the same direction. Unfortunately, the genome is well known to be "noisy" due to the fact that the vast majority of variants represent background variation rather than having any phenotypic effect even in causal genes. Furthermore, though the majority of newly arising mutations are believed to be deleterious, some others still may be beneficial (Nejentsev et al., 2009) . Thus, merging all rare variants equally regardless of their relative phenotypic impacts may produce an unsatisfactory "signal-to-noise" ratio.
To distinguish those likely causative variants from background variation, a variety of weighting schemes have been proposed in the literature (Madsen & Browning, 2009; Han & Pan, 2010; Liu & Leal, 2010; Price et al., 2010; Zhang et al., 2010a; Zhang et al., 2010b; Ionita-Laza et al., 2011; Sul et al., 2011; Yi & Zhi, 2011) . Therein, Madsen & Browning (2009) weight each variant according to its population frequency so that rarer variants obtain a heavier weight. The hypothesis underlying this weighting is that rarer variants render a larger per-allele phenotypic effect. Price et al. (2010) extend this work by weighting only variants with minor allele frequency (MAF) below a specified threshold, but they examine all MAF thresholds encountered in the sample. Despite their potential merit in enlarging mutation signals, MAF-based weighting schemes may be limited by the fact that the relationship between the frequency of an allele and its causative status is not well established. For instance, such schemes are unlikely to judge an allele as a causative one if it is even rarer in the normal population than in affected individuals. A more plausible scheme may base weight on both the strength and direction of individual association. However, a technical problem for this approach is that in a conventional frequentist manner, association signals are difficult to measure precisely for rare variants. The problem could be circumvented by taking a Bayesian view of point. In the Bayesian framework, the posterior distribution of association could be identifiable as long as an appropriate prior distribution is given (Yi & Zhi, 2011) .
Besides the data itself, another source of information that could be used to select potentially causal variants is the prior knowledge on each variant. Unlike neutral genetic markers, each variant in gene coding regions has biological impact on protein structure and function. The functional impact could be studied and predicted a priori by a variety of bioinformatic algorithms (Adzhubei et al., 2010; Ng & Henikoff, 2003; Ng & Henikoff, 2006; Mooney & Altman, 2003; Reumers et al., 2006) . Incorporating prior knowledge acquired by these algorithms into weighting on likely causal variants has the potential to improve the performance of association tests (Price et al., 2010) . However, the improvement is heavily dependent on the accuracy of prediction algorithms (Zhang et al., 2010a) . Thus, it is preferable to take the predicted functional impact as prior distribution rather than the sole source-to-weight variants.
In this study, in order to improve the power of the rare variant aimed association test, we propose a novel Bayesian method that integrates these two sources of information. Specifically, they are modelled into a single Bayesian marker selection framework to instruct the selection of likely causal variants. On the one hand, each rare variant is weighted according to its posterior association distribution. On the other hand, the predicted functional impact is modelled as prior distribution to facilitate highlighting likely causal variants. We will demonstrate the utility of our method by extensive simulation studies as well as by analysing two real datasets.
Methods

Definition
Throughout this study, we assume that rare variants are independent and present no interaction effect. Suppose a number of N individuals, including N d cases and N u controls, are sequenced at a genomic region of interest, and a total of L rare variants (MAF<5%) are discovered. Let d l be the total number of rare alleles carried by cases at the lth variant, and let
. . , u L ) for controls in the same manner. In addition, let R = (r 1 , . . . , r L ) represent the number of rare alleles carried by both cases and controls. The L variants are partitioned into three groups: group 0 contains variants that are irrelevant to the disease; group 1 contains variants at which rare alleles increase the risk of the disease, and group 2 contains variants at which rare alleles decrease the risk of the disease. Let I l = 0, 1, 2 indicate the membership of the lth variants, and let I = (I 1 , . . . , I L ). The genotypes of cases in the three groups are denoted by D 0 , D 1 , and D 2 , and those of controls are denoted by U 0 , U 1 , and U 2 , respectively.
Model
We extend a Bayesian marker partition model (Zhang & Liu, 2007 , Tang et al., 2009 to study the membership of variants. Variants in group 0 are irrelevant to the disease so that a rare allele at each variant has the same distribution between cases and controls. Suppose rare alleles follow a binomial distribution, and let θ 0 = (θ l , I l = 0) be the vector of rare allele frequency for variants in group 0. The likelihood of genotype data of the sample in group 0 is written by N is the binomial coefficient. Assuming that each θ l has a prior beta (α l , β l ) distribution, we integrate out θ 0 and obtain the marginal probability of genotypes in group 0
where B( . , . ) denotes the Beta function. Group 1 contains variants at which rare alleles increase the risk of disease so that a rare allele at each variant has a larger frequency in cases than in controls. Let θ 1 = (θ l , I l = 1) be rare allele frequencies for cases in group 1. To restrict each allele frequency in controls to be lower than that in cases, we introduce a vector of factor ξ 1 = {ξ l ∈(0, 1), I l = 1} so that allele frequency at each variant in controls ρ l = θ l x ξ l . The factor ξ l reflects the magnitude of discrepancy in allele frequency between cases and controls. In fact, 1/ξ l approximates the odds ratio for a very rare allele. Given θ 1 and ξ 1 , the likelihood of genotypes in group 1 is written by
Assume a prior beta (α l , β l ) distribution for each θ l and a prior beta (γ l1 , γ l2 ) distribution for each ξ l ; we integrate out θ 1 and ξ 1 and obtain the marginal probability of genotypes in group 1
Group 2 contains variants at which rare alleles decrease the risk of disease so that rare allele at each variant has a larger frequency in controls than in cases. In a similar manner to group 1, let θ 2 = (θ l , I l = 2) be rare allele frequencies of controls in group 2, and let ξ 2 = {ξ l ∈(0, 1), I l = 2} so that the allele frequency in cases equals θ l × ξ l . Assume a prior beta(α l , β l ) distribution for each θ l and a prior beta(γ l1 , γ l2 ) distribution for each ξ l ; we integrate out θ 2 and ξ 2 and obtain the marginal probability of the genotypes in group 2
Letting the prior distribution of I be P(I), we combine formulas (1)- (3) and obtain the posterior distribution of I
In the above formula, P(I) quantifies our prior knowledge of each of the variants belonging to each group. Denote p l0 , p l1 , and p l2 the prior probabilities for the lth variant belonging to each of the three groups, then P(I) has the following form:
where I l = k is an indicator variable that equals 1 if the statement holds and 0 otherwise.
Testing Association
The posterior distribution P(I|D,U) contains all information provided by the combination of prior knowledge and data together. The three probabilities corresponding to each variant facilitate statistical inference for various purposes. Here, we focus on variants in group 1 and test their association with the disease in a frequentist manner. We judge a variant to belong to group 1 if its posterior probability in group 1 is larger than that in groups 0 and 2. For each individual j, define a genetic score
where g jl = 0, 1, or 2 encodes the number of rare alleles carried by the individual at the lth variant. All genetic scores over cases and controls are ranked ascendingly and the sum of ranks of cases is obtained, termed as r D . A rank-sum test (Lehmann, 1999) could be performed, but the result will be biased due to the Bayesian marker selection procedure. Therefore, we instead take r D as the statistic and perform a series of Monte Carlo simulations to assess its significance. Specifically, we perform a number of k = 10,000 Monte Carlo permutations each by permuting case/control status. In each permuted dataset, we reperform the Bayesian variable selection procedure and obtain a value of r D. An exact p-value is obtained by dividing the number of replicates in which the value of r D is larger than that of the unpermuted sample by the total number of replicates. We term the test Bayesian Marker Selection Test (BMST).
Model Parameters
The parameters of the Bayesian marker selection model include the prior probability P(I); the hyperparameters α l and β l for allele frequency distribution; the hyperparameters γ l1 , γ l2 for the distribution of discrepancy of allele frequency.
The prior probability is a set of probability vectors quantifying our a priori belief of each variant being causal. Incorporating predicted functional impact by specialised algorithms has the ability to improve the power of association test, though it is largely dependent on the accuracy of prediction algorithms. When prior knowledge is not available, we set p l0 = p l1 = p l2 = 1/3. The distribution of rare allele frequency is estimated by analysing the real sequence data produced by the 1000 genomes pilot project (Durbin et al., 2010) . We focus on the exon dataset, which has the deepest coverage and the greatest number of sequenced individuals, of the European (CEU+TSI) population. Maximal likelihood estimation on all available data gives the estimate of Beta distribution (α, β) = (0.309, 2.024) (see the Appendix for details). Inference with only rare variants (MAF<5%) shifts the distribution to rare variants further with (α, β) = (0.328, 2.496). This latter estimate will be used as the prior distribution for all rare variants.
The discrepancy in allele frequency between cases and controls reflects the effect of the variant on the phenotype, and its distribution is quite subjective. We set the parameters (γ l1 , γ l2 ) = (0.5, 0.5) for all variants. Additional analyses on several other parameters give similar results.
Computing Issue
Since rare variants are assumed to be independent, the highdimensional posterior distribution of I can be transformed into the product of a series of posterior distributions of individual variants. For each individual variant, the posterior probability vector can be exactly computed. Therefore, no computationally demanding sampling procedure will be required. The most expensive computation is the calculation of a series of beta functions in equations (1)-(3). For the sake of speed, the intermediate results are stored for later access.
Comparison with Existing Methods
For comparison, we have included several existing methods into the analyses. These methods include: Collapsing (Li & Leal, 2008) ; Weighted-Sum (WS) (Madsen & Browning, 2009 ); Variable Threshold weighted sum (VT) (Price et al., 2010) ; Rare Cover (RC) (Bhatia et al., 2010) ; Kernel-Based Adaptive Cluster (KBAC) (Liu & Leal, 2010) ; and Replication-based Weighting (RW) (Ionita-Laza et al., 2011) . For WS and VT, we invoke the R package rareVariantTests.R provided in Price et al. (2010) and retrieve the p-values score3p and score4p, respectively. For KBAC, we invoke the program kbac provided in Liu & Leal (2010) . For RW, we invoke the program test_rare provided in Ionita-Laza et al. (2011) . The other tests are implemented by our in-house software. All parameters are set to default values suggested by the respective authors. Specifically, for RC, the convergence cutoff is set to 0.5, and the window size to 5 kb. Notice that default settings may not represent the optimal performance of these methods.
Simulation Studies
To systematically investigate the performance of the proposed method under a variety of conditions, we conducted a series of simulation studies. We focused on the European population and simulated a gene coding region by a demographic model (Williamson et al., 2005) , which can account for the change in size of the population. This complex model assumes that the European population experienced a bottleneck, followed by a long duration of recovery, then by a rapid expansion to the modern population. It has a total of seven parameters: the effective size of ancestral (7947), bottleneck (262), recovery (7019), and current populations (52,907); the duration (in unit of generation) of bottleneck (84), recovery (4557), and recent expansion (576), respectively. The values of these parameters were estimated in Boyko et al. (2008) . In addition, both mutation and recombination rates were set to 1.0 × 10 −8 per site. To account for the effect of natural selection, we added a distribution of selection coefficient to newly arising mutations, where the distribution was taken from a "neutral+gamma" form. The parameters of the distribution were estimated in (Boyko et al., 2008) . Specifically, a proportion of 0.239 of newly arising mutations were modeled as neutral, while the remainder were suffering negative selection with selection coefficients drawn from the gamma distribution Gamma (1.02, 800). The gene was simulated with two lengths: 10 and 20 kb. The simulation was performed by an extensive forward simulation program sfs_code (Hernandez, 2008 The output from sfs_code contained all derived mutations and their frequencies, which were taken as the template to simulate genotypes. We simulated a pool of 10,000 quantitatively phenotyped individuals and selected cases/controls from two tails of phenotypic distribution. Genotypes for each individual were simulated according to allele frequencies with the assumption of Hardy-Weinberg equilibrium. Common variants (MAF≥5%) and monosites, which present no variation in the simulated sample, were removed. On simulating the phenotype, a set C of causative variants was randomly selected with a specified proportion. For individual j, define a genetic risk score as
The quantitative phenotype was generated by a linear regression equation
where μ was the grand phenotypic mean; e j was the random error that followed a normal distribution with zero mean. The coefficient β was determined by gene heritability h 2 , which was defined as
where var(r) was the variance of risk score across the sample and var(e) was the variance of random error. After the phenotype was generated, a specified number of individuals with highest phenotypes were selected as cases and an equal number of individuals with lowest phenotypes were selected as controls. As a baseline, we set the proportion of causative variants to be equal to 30%, the gene heritability to 0.5%, and the number of cases/controls to 1000/1000.
To evaluate the effect of predicted functional impact of variants on power estimation, we simulated the functional impacts given by the prediction algorithms. The accuracy of a particular prediction algorithm is measured by its sensitivity and specificity. Here, the sensitivity is defined as the probability that a causative variant is correctly predicted, and the specificity as the probability that a noncausative variant is incorrectly predicted as a causative one. We assumed that the sensitivity and the specificity were α and β. We used a probability p of being causative as the continuous measure given by the prediction algorithm. Let O be an indicator of predicted causative variant, and let R be an indicator of causative variant. Specifically, we had P (O = 1|R = 1) = α, and P (O = 1|R = 0) = β. Given R = 1 or 0, O was drawn from a Bernoulli distribution Ber(α) or Ber(β). We then simulated p from the Uniform distribution U(t, 1) or U(0, t) given O = 1 or 0, where t is a threshold to declare a causative variant by the prediction algorithm. In this simulation, we set t = 0.5. Given p, the probability that a variant is either neutral or protective was set to (1−p)/2.
One explicit assumption in our Bayesian model is the independence among variants. To test its robustness to the violation of this assumption, we also simulated variants with linkage disequilibrium (LD) structures. Specifically, we added the following step before generating the phenotype. A specified proportion of 30% of variants were randomly selected, and all subjects' genotypes at each variant were permuted so that the rare allele was in complete LD (D = 1) with the rare allele at its nearest neighbouring variant. Subsequent simulations were the same as above.
The simulation studies were conducted at a variety of parameter settings. At each setting, 10,000 replicates were performed to estimate the power rate. Both type-I error and power were estimated at two significance levels: 0.01 and 0.001. Model parameters for the proposed test were set to the following: the prior distribution of a rare allele was Beta (0.328, 2.496). The prior distribution of discrepancy between cases and controls was Beta (0.5, 0.5). The prior weights of alleles being risk, neutral, and protective were (0.33, 0.33, 0.33) in the absence of prior knowledge.
Applications
We reanalysed two publicly available studies published by Cohen et al. (2004 Cohen et al. ( , 2006 . In the first study, in order to examine the association of rare variants with HDL-C level in three candidate genes (ABCA1, APOA1, and LCAT), Cohen et al. (2004) sequenced the three genes in one group consisting of 128 individuals with low HDL-C levels and another group of 128 individuals with high HDL-C levels. To validate their findings, they sequenced the same three genes in a second sample consisting of 155 individuals with low HDL-C levels and 108 individuals with high HDL-C levels. These two samples were combined and analysed together. As the authors did, we combined the three genes together and analysed rare variants that are unique to either the high or the low group. The resultant data include 35 variants that are exclusive to the low group and five variants that are exclusive to the high group
In the second study, Cohen et al. (2006) used the same strategy and sequenced the gene NPC1L1 in one group consisting of 256 individuals with low Ca:L ratios and another group of 256 individuals with high Ca:L levels, in order to examine the association of identified rare variants with LDL-C level. Again, we analysed rare variants unique to either the high or low group, as the authors did. A total of 25 rare variants were analysed, among which 20 are exclusive to the low group and the other five are exclusive to the high group. Note: A total of 1000 cases and 1000 controls were simulated at two gene lengths: 10 and 20 kb. Type-I error rates were estimated at target levels 1.0% and 0.10% by performing 10,000 replicates. Abbreviations: BMST, the proposed Bayesian marker selection test; KBAC, the kernel-based adaptive cluster test (Liu & Leal, 2010) ; RC, the rare cover test (Bhatia et al., 2010) ; VT, the variable threshold test (Price et al., 2010) ; WS, weighted sum test (Madsen & Browning, 2009 ); RW, replication-based weighting test (Ionita-Laza et al., 2011) ; Collapsing, collapsing test (Li & Leal, 2008) . 
Results
Type-I Error
Power Estimate
Figure 1 depicts the power estimate for a 10-kb gene length in the absence (upper panel) or presence of LD (lower panel). As expected, all tests have improved power with increased gene heritability. Among the tests, the proposed BMST has the highest power when the heritability is below 0.6; otherwise, RW is more powerful. Their powers are followed by KBAC and VT, where KBAC is more powerful than VT in most cases. They are then followed by WS and RC, which generally have approximately equal power. Finally, Collapsing has the lowest power in most cases. For BMST, the heritability at which the gene is detected with 80% power is approximately 0.5%, while that for RW, KBAC, VT, RC, and WS are 0.6, 0.6, 0.7, 0.9, and 1.0%, respectively. Collapsing can only achieve power of around 70% even at a heritability as high as 1.0%. In the presence of LD, the trends of power for various tests are similar to those in the absence of LD. Figure 2 displays power estimate for a 20-kb gene length. Again, all tests have improved power with increased heritability. Among the tests, BMST has the uniform highest power in all settings, followed by RW, then by KBAC and VT, whose powers are approximately equal. Among the other three tests whose powers are less than those mentioned above, WS is superior to both RC and Collapsing, where the latter two tests perform generally equally. Again, power estimates in the presence of LD do not change significantly (lower panel). Therefore, we report results only in the absence of LD in what follows.
Comparison of power at 10 and 20 kb gene lengths (Fig. 3 ) shows that power is decreased with a longer gene for most tests; however, different tests have different sensitivities. RC is most sensitive to gene length as it shows the greatest power loss, followed by KBAC, Collapsing, RW, and VT. For BMST and WS, power is nearly unchanged under the two lengths.
When the predicted functional impacts of individual variants are informative, the usage of such prior knowledge could improve the performance of tests, as displayed in Figure 4 , in which the sensitivity and specificity of prediction are set to 0.6 and 0.2. All of the four tests that incorporate prior information into weighting variants have improved power. The magnitude of power improvement for BMST is around 3%, slightly lower than that for the other tests, which are 6% for VT, 5% for WS, and 6% for RW.
We also investigated the performance of tests when functional prediction is noninformative. To simulate this scenario, we generated for each variant a continuous prediction measure from the Uniform distribution U (0, 1), independent of its causative status. As listed in Table 2 , all four tests have power lost, where the magnitude of the loss is approximately 8% for BMST, 10% for VT, 16% for WS, and 12% for RW.
Computation Time
Computation time was measured by analysing a simulated sample with 1000/1000 individuals and 10 kb gene length. The number of permutations was set to 10,000. Running on a single Intel 2.8 GHz CPU, the computation time was 69 s (seconds) for BMST, 41 s for RC, 13 s for Annals of Human Genetics (2012) 76,74-85 79 Figure 1 Power with 10 kb gene length. A pool of 10,000 quantitatively phenotyped individuals was generated, from which 1000/1000 individuals with extreme phenotypes were selected as cases/controls. A gene with 10 kb length was simulated, with gene heritability varying from 0.1% to 1.0%. Power was estimated at significance level 1% with 10,000 replicates. Both the absence (upper panel A) and presence (lower panel B) of LD among rare variants were simulated. KBAC, 5 s for RW, 2 s for VT, 1 s for WS, and <1 s for Collapsing. Scaling the configuration to a computer cluster with 8 or 16 CPUs on each computing node, BMST could complete a genome-wide scan (∼20,000 genes) within days, thus making it applicable to large-scale association scans.
Applications
As applications, we reanalysed the two studies described in the above section and examined the association of identified rare variants with the two traits HDL-C and LDL-C, respectively. The analyses are listed in Table 3 . Obviously, all tests have the ability to detect the association. However, BMST has lower p-values than most of the other tests, implicating its efficacy.
We then predicted the functional impact of each variant and incorporated the prediction results into the test. Variants were predicted by a popular server PolyPhen-2 (Adzhubei et al., 2010) , which outputs one of three categories for each variant: "benign," "Possibly damaging," and "Probably damaging." We assign "benign" variants a prior probability 1/3, "Possibly damaging" variants 1/2, and "Probably damaging" variants 5/6, of being causative. PolyPhen-2 could not give a prediction for nonsense mutations. As nonsense mutations disrupt protein structure, they tend to damage protein function. Therefore, we divided them into the "Probably damaging" category and assign a prior probability 5/6. The association results are listed in Table 4 . For BMST, association signals were boosted in both samples, indicating the value of using prior information. For the other tests, their association signals were boosted in the LDL-C sample, but remain unchanged or instead were elevated in the HDL-C sample. Scrutiny of this sample indicates that several mutations in the case group are predicted as "benign." Weighting variants directly by these predictions may reduce association signal in the case group. Instead, by specifying these predictions as prior distribution, BMST still has the opportunity to pick them up through posterior distribution.
Discussion
In this study, we have proposed a novel method to test the association of rare variants and complex diseases. By modelling in a Bayesian marker selection framework, we incorporated two sources of information to highlight likely causal variants: individual association signal and prior knowledge of functional impact. Simulation studies showed that the proposed method outperformed several existing methods in certain conditions. The proposed method was applicable to large-scale association scans. Note: A pool of 10,000 quantitatively phenotyped individuals was generated, from which 1000/1000 individuals with extreme phenotypes are selected as cases/controls. Gene heritability was set to 0.5%. Prior probability was simulated from the Uniform distribution U(0, 1), independent of the causal status of variants. Power was estimated at significance level 1.0% with 10,000 replicates.
Interaction between rare variants could also be a cause of complex diseases (Liu & Leal, 2010) , and it is easy to extend the proposed method to include interaction effects (Zhang & Liu, 2007) . However, there is a fundamental distinction in the analyses of interaction effects for rare and common variants. For a two-way interaction model, three genotypes at each locus correspond to nine possible two-locus genotype combinations. For common variants, each combination could be interpreted as an interaction effect. For rare variants, however, because it is rare alleles that are suspected to be causative, only combinations between rare alleles could be interpreted as an interaction effect. This interpretation reduces the number of combinations of interest from nine to four. Furthermore, the occurrence of the homozygous mutant genotype is much rarer, so only one joint combination is left to be of primary interest to detect an interaction effect.
For modelling simplicity, we assume independence among rare variants. However, our method is still valid when this assumption is violated, as demonstrated by our simulation Note: The functional impact of each variant was predicted by PolyPhen-2 (Adzhubei et al., 2010) . Three categories: "Benign," "Possibly damaging," and "Probably damaging," given by PolyPhen-2 were converted into three prior probabilities: 1/6, 3/6, and 5/6. p-values were estimated by 1 × 10 7 permutation replicates, but for BMST, 1 × 10 8 replicates were performed.
results. We also notice that most of the existing groupingbased tests (except KBAC) implicitly assume independent effects among variants regardless of the presence of LD, because for these tests when mutation signals of multiple variants are merged, the patterns of LD among them are also collapsed. In fact, assuming the rare allele at a second variant to be in LD with the causal rare allele is equivalent to assuming two causal alleles. In this study, we implement a one-sided test by examining the existence of causal variants. The test of protective variants is straightforward to implement in the same manner. Alternatively, a two-sided test could be constructed by combining association signals of these two groups of variants together. A two-sided test is expected to be more powerful than a one-sided test in the presence of both causal and protective effects. However, most of the current empirical studies focus only on identifying disease-causing mutations, resulting in fewer studies on the distribution of protective variants.
Our method is applicable to analysing arbitrary genomic regions, though we focus our analyses on gene-coding regions. The prior information of variants at noncoding regions could be evaluated and predicted by studying orthologous sequences. However, it is still challenging to specify a proper prior distribution according to the conservation of variants, Note: For the HDL-C sample, 283 individuals with low HDL-C levels and 236 individuals with high levels were sequenced at three genes (ABCA1, APOA1, and LCAT). A total of 40 rare variants in the three genes were combined and analysed together. Of these variants, 35 are exclusive to the low group and the other five are exclusive to the high group. For the LDL-C sample, 256 individuals with low Ca:L ratios and 256 individuals with high ratios were sequenced at gene NPC1L1. A total of 25 rare variants were combined and analysed together. Of these variants, 20 are exclusive to the low group and the other five are exclusive to the high group. p-values were estimated by 1 × 10 because sequence conservation and phenotype variation are not well correlated (Ahituv et al., 2007b) . Common variants are an important source of genetic variation for complex diseases as well. When common and rare variants are analysed together, a multivariate method should be adopted. Specifically, the mutation signals synthesised by analysing the groups of rare variants and common variants should be analysed jointly in a multivariate model.
In conclusion, we propose a novel method to test the association of multiple rare variants and complex diseases. The program implementing our method is available upon request from the authors.
APPENDIX
Assume that N chromosomes are studied. We follow (IonitaLaza et al., 2009 ) and define the site-frequency spectrum of sample configuration as the random vector X = (X 1 , X 2 , . . ., X N −1 ), where X i represents the number of sites that carry N-i copies of ancestral alleles and i copies of derived alleles (1≤i≤N-1) . Assuming the frequency p of derived alleles follows a Beta (α, β) distribution, with the probability
B(α, β) .
For each site, the probability that i copies of derived allele are observed in the sample is
Summing over ancestral and derived alleles, the probability that minor alleles are observed i (1≤i<N/2) times is . The parameters are estimated by maximizing the likelihood. To search the maximum of the likelihood, we vary each of α and β in the interval (0.1, 10) at the step size 0.001, and exhaust all combinations of (α, β). At each combination, the likelihood is computed. The combination corresponding to the maximal likelihood will be the parameters sought.
